BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

239 related articles for article (PubMed ID: 21990218)

  • 1. Impact of average weekly dose of radiation during radiotherapy alone or chemoradiotherapy in head and neck cancer.
    Dragovic AF; Bonner JA; Spencer SA; Nabell LM; Carroll WR; Caudell JJ
    Head Neck; 2011 Nov; 33(11):1551-6. PubMed ID: 21990218
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Individualized treatment of head neck squamous cell carcinoma patients aged 70 or older with radiotherapy alone or associated to cisplatin or cetuximab: impact of weekly radiation dose on loco-regional control.
    Belgioia L; Bacigalupo A; Missale F; Vecchio S; Chiola I; Callegari S; Verzanini E; Peretti G; Corvò R
    Med Oncol; 2019 Mar; 36(5):42. PubMed ID: 30927146
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Survival impact of induction chemotherapy in advanced head and neck cancer: A National Cancer Database analysis.
    Stokes WA; Amini A; Jones BL; McDermott JD; Raben D; Ghosh D; Goddard JA; Bowles DW; Karam SD
    Head Neck; 2017 Jun; 39(6):1113-1121. PubMed ID: 28301079
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Locally advanced head and neck cancer treated with accelerated radiotherapy, the hypoxic modifier nimorazole and weekly cisplatin. Results from the DAHANCA 18 phase II study.
    Bentzen J; Toustrup K; Eriksen JG; Primdahl H; Andersen LJ; Overgaard J
    Acta Oncol; 2015 Jul; 54(7):1001-7. PubMed ID: 25629651
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Systematic Review and Meta-analysis of Conventionally Fractionated Concurrent Chemoradiotherapy versus Altered Fractionation Radiotherapy Alone in the Definitive Management of Locoregionally Advanced Head and Neck Squamous Cell Carcinoma.
    Gupta T; Kannan S; Ghosh-Laskar S; Agarwal JP
    Clin Oncol (R Coll Radiol); 2016 Jan; 28(1):50-61. PubMed ID: 26454839
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Weekly Low-Dose Versus Three-Weekly High-Dose Cisplatin for Concurrent Chemoradiation in Locoregionally Advanced Non-Nasopharyngeal Head and Neck Cancer: A Systematic Review and Meta-Analysis of Aggregate Data.
    Szturz P; Wouters K; Kiyota N; Tahara M; Prabhash K; Noronha V; Castro A; Licitra L; Adelstein D; Vermorken JB
    Oncologist; 2017 Sep; 22(9):1056-1066. PubMed ID: 28533474
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Functional organ preservation after chemoradiotherapy in elderly patients with loco-regionally advanced head and neck squamous cell carcinoma.
    Boscolo-Rizzo P; Muzzi E; Trabalzini F; Gava A; Stellin M; Da Mosto MC
    Eur Arch Otorhinolaryngol; 2011 Sep; 268(9):1349-55. PubMed ID: 21258812
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hypopharyngeal squamous cell carcinoma: Three-dimensional or Intensity-modulated radiotherapy? A single institution's experience.
    Katsoulakis E; Riaz N; Hu M; Morris L; Sherman E; McBride S; Lee N
    Laryngoscope; 2016 Mar; 126(3):620-6. PubMed ID: 26597398
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Concurrent cetuximab versus platinum-based chemoradiation for the definitive treatment of locoregionally advanced head and neck cancer.
    Tang C; Chan C; Jiang W; Murphy JD; von Eyben R; Colevas AD; Pinto H; Lee-Enriquez N; Kong C; Le QT
    Head Neck; 2015 Mar; 37(3):386-92. PubMed ID: 24431011
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Randomized phase III study of 2 cisplatin-based chemoradiation regimens in locally advanced head and neck squamous cell carcinoma: impact of changing disease epidemiology on contemporary trial design.
    Rodriguez CP; Adelstein DJ; Rybicki LA; Savvides P; Saxton JP; Koyfman SA; Greskovich JF; Yao M; Scharpf J; Lavertu P; Wood BG; Burkey BB; Lorenz RR; Rezaee RP; Zender CA; Ives DI
    Head Neck; 2015 Nov; 37(11):1583-9. PubMed ID: 24909549
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Postoperative concurrent chemotherapy and radiotherapy for high-risk cutaneous squamous cell carcinoma of the head and neck.
    Tanvetyanon T; Padhya T; McCaffrey J; Kish JA; Deconti RC; Trotti A; Rao NG
    Head Neck; 2015 Jun; 37(6):840-5. PubMed ID: 24623654
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Outcomes of intensity-modulated radiotherapy versus conventional radiotherapy for hypopharyngeal cancer.
    Mok G; Gauthier I; Jiang H; Huang SH; Chan K; Witterick IJ; O'Sullivan B; Waldron JN; Bayley AJ; Cho BC; Cummings BJ; Dawson LA; Hope AJ; Kim JJ; Ringash J
    Head Neck; 2015 May; 37(5):655-61. PubMed ID: 24590756
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Induction chemotherapy and concurrent chemoradiotherapy for locoregionally advanced head and neck cancer: a multi-institutional phase II trial investigating three radiotherapy dose levels.
    Salama JK; Stenson KM; Kistner EO; Mittal BB; Argiris A; Witt ME; Rosen F; Brockstein BE; Cohen EE; Haraf DJ; Vokes EE
    Ann Oncol; 2008 Oct; 19(10):1787-94. PubMed ID: 18539617
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Value of intensity-modulated radiotherapy in Stage IV head-and-neck squamous cell carcinoma.
    Dirix P; Nuyts S
    Int J Radiat Oncol Biol Phys; 2010 Dec; 78(5):1373-80. PubMed ID: 20362402
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High survival and organ function rates after primary chemoradiotherapy for intermediate-stage squamous cell carcinoma of the head and neck treated in a multicenter phase II trial.
    Cohen EE; Haraf DJ; List MA; Kocherginsky M; Mittal BB; Rosen F; Brockstein B; Williams R; Witt ME; Stenson KM; Kies MS; Vokes EE
    J Clin Oncol; 2006 Jul; 24(21):3438-44. PubMed ID: 16849759
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Concomitant cisplatin significantly improves locoregional control in advanced head and neck cancers treated with hyperfractionated radiotherapy.
    Huguenin P; Beer KT; Allal A; Rufibach K; Friedli C; Davis JB; Pestalozzi B; Schmid S; Thöni A; Ozsahin M; Bernier J; Töpfer M; Kann R; Meier UR; Thum P; Bieri S; Notter M; Lombriser N; Glanzmann C
    J Clin Oncol; 2004 Dec; 22(23):4665-73. PubMed ID: 15534360
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Randomized trial comparing surgery and adjuvant radiotherapy versus concurrent chemoradiotherapy in patients with advanced, nonmetastatic squamous cell carcinoma of the head and neck: 10-year update and subset analysis.
    Iyer NG; Tan DS; Tan VK; Wang W; Hwang J; Tan NC; Sivanandan R; Tan HK; Lim WT; Ang MK; Wee J; Soo KC; Tan EH
    Cancer; 2015 May; 121(10):1599-607. PubMed ID: 25639864
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Concurrent cetuximab and postoperative radiation in resected high-risk squamous cell carcinomas of the head and neck: A single-institution experience.
    Araki D; Redman MW; Martins R; Eaton K; Baik C; Chow L; Goulart B; Lee S; Santana-Davila R; Liao J; Parvathaneni U; Laramore G; Futran N; Mendez E; Bhrany A; Rodriguez CP
    Head Neck; 2016 Sep; 38(9):1318-23. PubMed ID: 27061333
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cervical lymph node metastases from unknown primary cancer: a single-institution experience with intensity-modulated radiotherapy.
    Villeneuve H; Després P; Fortin B; Filion E; Donath D; Soulières D; Guertin L; Ayad T; Christopoulos A; Nguyen-Tan PF
    Int J Radiat Oncol Biol Phys; 2012 Apr; 82(5):1866-71. PubMed ID: 21497452
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Final Results of a Randomized Phase 2 Trial Investigating the Addition of Cetuximab to Induction Chemotherapy and Accelerated or Hyperfractionated Chemoradiation for Locoregionally Advanced Head and Neck Cancer.
    Seiwert TY; Melotek JM; Blair EA; Stenson KM; Salama JK; Witt ME; Brisson RJ; Chawla A; Dekker A; Lingen MW; Kocherginsky M; Villaflor VM; Cohen EE; Haraf DJ; Vokes EE
    Int J Radiat Oncol Biol Phys; 2016 Sep; 96(1):21-9. PubMed ID: 27511844
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.